HK inno.N Corporation
195940 | KO
Overview
Corporate Details
- ISIN(s):
- KR7195940002
- LEI:
- Country:
- South Korea
- Address:
- 충청북도 청주시 흥덕구 오송읍 오송생명2로 239 에이치케이이노엔(주) 오송공장, 청주시
- Website:
- https://www.inno-n.com/eng
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.5 MB | ||
| 2025-07-30 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 6.6 KB | ||
| 2025-07-30 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 6.7 KB | ||
| 2025-07-30 00:00 |
Earnings Release
영업(잠정)실적(공정공시)
|
Korean | 14.4 KB | ||
| 2025-07-24 00:00 |
Report Publication Announcement
결산실적공시예고
|
Korean | 4.1 KB | ||
| 2025-06-30 00:00 |
Environmental & Social Information
지속가능경영보고서등관련사항(자율공시)
|
Korean | 10.6 KB | ||
| 2025-06-19 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 6.6 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.3 MB | ||
| 2025-05-07 00:00 |
Regulatory Filings
투자판단관련주요경영사항(임상시험계획승인신청등결정) (IN-B00009의 제3상 임상시험계획 승인)
|
Korean | 10.7 KB | ||
| 2025-04-30 00:00 |
Regulatory Filings
소속부변경
|
Korean | 3.6 KB | ||
| 2025-04-28 00:00 |
Earnings Release
영업(잠정)실적(공정공시)
|
Korean | 14.4 KB | ||
| 2025-04-28 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 6.6 KB | ||
| 2025-04-28 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 6.6 KB | ||
| 2025-04-22 00:00 |
Report Publication Announcement
결산실적공시예고
|
Korean | 4.1 KB | ||
| 2025-03-26 00:00 |
AGM Information
정기주주총회결과
|
Korean | 20.7 KB |
Automate Your Workflow. Get a real-time feed of all HK inno.N Corporation filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for HK inno.N Corporation
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for HK inno.N Corporation via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America
INCY
United States of America
INCY
Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.
United Kingdom
INDV
United Kingdom
INDV
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden
IBT
Sweden
IBT
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America
IKT
United States of America
IKT
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America
INBX
United States of America
INBX
Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.
United States of America
INM
United States of America
INM
Develops immunotherapies reprogramming innate immunity for cancer, Alzheimer's, and inflammation.
United States of America
INMB
United States of America
INMB
Clinical-stage biotech developing NK cell-engaging antibodies for cancer immunotherapy.
France
IPH
France
IPH
Develops research-driven anti-aging solutions for skin regeneration and hair follicle formation.
South Korea
344860
South Korea
344860
Develops DNA medicines delivered via smart devices for cancer, HPV, and infectious diseases.
United States of America
INO
United States of America
INO